Jiangsu Vcare Unveils Phase I Clinical Trial Results of TRK Inhibitor VC004 at 2024 ASCO
Published Time:
2024-06-07 17:08
Source:
On June 2, 2024，Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) unveiled the Phase I clinical trial results of its self-developed next-generation TRK inhibitor, VC004, for the treatment of locally advanced/metastatic solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract ID: #3101
This study is a first-in-human, multicenter, single-arm, open-label Phase I/II clinical trial (ClinicalTrials.gov Identifier: NCT04614740). The Phase I portion is designed to evaluate the safety, efficacy, and pharmacokinetic (PK) profile of VC004 in patients with locally advanced/metastatic solid tumors.
Key Findings: During the Ib dose-expansion phase, 35 patients (median age: 57.0 years; 97% with ECOG score ≤1) treated with VC004 50 mg twice daily (recommended Phase II dose, RP2D) achieved unconfirmed and confirmed ORRs of 75.9%(95% CI: 56.5–89.7) and 69.0%(95% CI: 49.2–84.7), respectively, as assessed by RECIST v1.1 criteria.
In the subgroup of patients naive to TRK-TKI treatment, the unconfirmed and confirmed ORRs reached 80.8%(95% CI: 60.6–93.4) and 73.1%(95% CI: 52.2–88.4), respectively. Median DoR and PFS were not yet reached. Notably, 28.6% of TRK-TKI treatment-naive patients maintained responses for ≥12 months, and 75.8% achieved PFS ≥9 months. Among three patients who progressed after prior TRK-TKI therapy, two exhibited tumor shrinkage, including one partial response (PR; 39.6%). Of six patients with baseline brain metastases, two experienced intracranial lesion reductions of 61.8% and 25%, while non-target lesions achieved complete resolution in two others after four months of treatment.
Safety Profile, TRAEs were predominantly Grade 1–2, with no fatal TRAEs reported. Common TRAEs (≥20%) included dizziness, weight gain, hypertriglyceridemia, anemia, elevated alanine aminotransferase (ALT), elevated aspartate aminotransferase (AST), hypercholesterolemia, and hyperuricemia. No new safety signals were observed compared to other TRK inhibitors.
VC004 demonstrated dose-proportional exposure across doses of 25–200 mg and favorable oral bioavailability.
VC004 exhibited safety comparable to first-generation TRK-TKIs and robust efficacy against NTRK fusion-positive tumors. Significant clinical benefits were observed not only in TRK-TKI treatment-naive patients but also in those with TRK-TKI resistant disease or baseline brain metastases.
Note: All data are preliminary and subject to confirmation in ongoing trials.
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn